~ What You Don't Know About Blood Sugar
In our relentless review of the scientific literature, we have uncovered data that calls into question what the safe range of blood sugar really is. Current guidelines state that a person is diabetic if fasting blood glucose levels exceed 126 mg/dL on two consecutive occasions. Fasting glucose levels over 109 are flagged as potential prediabetic (glucose intolerant) states. Life Extension has long argued that optimal glucose ranges are less than 100.
In a new hypothesis that shakes the pillars of conventional wisdom, it now appears that optimal fasting blood glucose levels should probably be under 86 mg/dL. This means that those with high "normal" glucose (86-109) are at an increased risk of premature death. While the medical establishment clearly understands the lethal dangers of hyperglycemia (blood sugar over 126), they have yet to recognize that even high normal glucose levels pose a serious threat to one's health.
Conventional Medicine's Interpretation of Fasting Glucose Blood Tests
|70-109 mg/dL||Normal glucose tolerance
|110-125 mg/dL||Impaired fasting glucose (prediabetes)
|126+ mg/dL||Probable diabetes
Life Extension's Fasting Glucose Guidelines
|70-85 mg/dL||Optimal (no glucose intolerance)
|86-99 mg/dL||Borderline impaired fasting glucose
|100+ mg/dL||Probable prediabetes
Why "Normal" Glucose Levels Are Dangerous
To support our hypothesis that higher "normal" ranges of blood glucose represent a health risk, we first investigated the multifaceted toxic effects that sugar inflicts throughout the body. We found many studies showing that sugar damages cells via multiple mechanisms and is a causative factor in common diseases of aging.1-37 It thus appears desirable to maintain the lowest level of blood glucose needed to sustain healthy metabolic function.
We then looked at the effects of caloric restriction, and noted one study in which fasting glucose declined from an average of 92 to 74 mg/dL in a group of adults who reduced their food intake.38 This corresponded to animal studies in which caloric restriction induced significant reductions in blood glucose levels.39-41 It is well established that cutting calorie intake reduces one's risk of age-related diseases and probably slows aging itself.42-50 One reason for this may be the reduction in blood glucose levels that occurs in response to ingesting fewer calories.
As people age, their fasting glucose levels normally increase as their health declines. Standard laboratory reference ranges show an aging person having a "normal" fasting glucose level of up to 109 mg/dL. Yet the most effective anti-aging therapy?aloric restriction?owers glucose levels to the low 70s (mg/dL).
Many theories of aging focus on the deleterious effects of glucose itself. Only a few studies have evaluated disease risk in people whose fasting blood glucose levels are in normal ranges. One study of nearly 2,000 men looked at fasting blood glucose levels over a 22-year period. Its startling results showed that men with fasting glucose levels over 85 mg/dL had a 40% increased risk of death from cardiovascular disease. The researchers concluded, "fasting blood glucose values in the upper normal range (appear) to be an important independent predictor of cardiovascular death in nondiabetic apparently healthy middle-aged men."51
We compiled data from all fasting glucose tests conducted over the past 12 months. The average reading was 94 mg/dL. While physicians would consider this "normal" result to be excellent, our new hypothesis indicates that optimal glucose levels should be below 86 mg/dL (and ideally as low as 74 mg/dL).
Where Your Pancreas Thinks Glucose Levels Should Be
The pancreas plays a major role in regulating blood glucose levels by secreting insulin to transport sugar out of the blood and into cells for energy production or storage.
Insulin also drives fat into cells, prevents fat from being released from cells, and makes people hungry. High insulin levels contribute to obesity and the disease states associated with being overweight, such as type II diabetes, cardiovascular disease, kidney failure, and certain types of cancers.
In normal health, the pancreas stops secreting insulin when glucose levels drop below 83 mg/dL.52-54 As I noted earlier, healthy aging people typically have fasting glucose levels over 90 mg/dL, and even competent doctors wait until fasting glucose is over 109 before suspecting a pre-diabetic (glucose-intolerant) condition.
But insulin continues to be secreted when blood glucose levels are over 83 mg/dL, which indicates that the pancreas is striving to drive glucose levels down to a range safer than what aging people typically are able to achieve.
Overweight and obese people have very high insulin levels.55-56 Chronically elevated insulin contributes to a host of degenerative diseases.57-63 Our new hypothesis suggests that lowering fasting glucose levels results in an even greater reduction in fasting insulin. By secreting insulin when blood sugar levels exceed 83 mg/dL, the pancreas is telling us to keep blood glucose far below the high "normal" reference ranges used by blood test labs. While today's standard fasting glucose reference range extends to 109 mg/dL before flagging a problem, our new hypothesis suggests that fasting glucose over 85 mg/dL is cause for concern.
Excess blood glucose induces enormous damage to tissues throughout the body. The question is, what to do about it?
Ways to Lower Blood Glucose
The safest, most effective way to lower blood glucose levels is caloric restriction. Few people, however, are able to consistently under-eat. Consuming a lower glycemic index/load diet reduces blood glucose levels somewhat.64-69
Chromium supplements have been shown to reduce blood glucose significantly.70-74 The dose used in human studies ranges from 200 to 1000 mcg of elemental chromium a day, with best results occurring when 400 mcg or more of chromium is taken daily.
Of interest is an animal study showing that chromium extended mean and maximum life span.75 This study surprised gerontologists, as chromium had not been considered a particularly promising antiaging nutrient. It may have been chromium's effect in lowering glucose levels that resulted in the significant prolonging of life span demonstrated in this study.
Magnesium, carnitine, alpha lipoic acid, and biotin also can help maintain glycemic control.76-108 A prescription drug for diabetes called metformin significantly lowers glucose levels in most people, but not everyone can take this medication.109-119
Nutrients That Have Been Shown to Reduce Fasting Blood Glucose Levels (primarily in diabetic patients): Alpha Lipoic acid81-94, Biotin98-108, Carnitine95-6, Chromium70-4, Magnesium76-80, Vanadium146-50, Zinc138-45
Regrettably, many aging people will not be able to maintain optimal blood glucose levels of less than 86 mg/dL. In this situation, protecting the body from the toxic effects of glucose becomes paramount. Glycation is a pathological process that occurs when glucose binds to protein molecules, resulting in the formation of non-functioning structures in the body. Higher blood glucose levels mean more-damaging glycation reactions.
Glycation advances slowly and accompanies every fundamental process of cellular metabolism. Glycation accelerates aging and neurodegenerative disorders such as Alzheimer's disease. Fortunately, a nutrient called carnosine confers significant protection against glycation processes.120-121
Higher blood glucose also causes increased oxidative stress. Consumption of antioxidants has shown beneficial results in type II diabetics.122-150 Based on our hypothetical definition that blood sugar over 85 mg/dL is too high, antioxidants may be more important to healthy people than previously thought.
A new fat-soluble form of vitamin B1 has demonstrated significant protection against sugar toxicity at the cellular level. In Europe, this vitamin B1 derivative called benfotiamine is prescribed for those suffering from disorders related to sugar toxicity, such as peripheral neuropathy. The good news is that this nutrient has been added to popular supplements already being taken by most Life Extension members. Consumers can thus help protect themselves against the lethal dangers of excess sugar (glucose) without having to swallow more capsules or spend more money.
Why Our Hypothesis May Revolutionize Antiaging Medicine
Despite their efforts to lead healthier lifestyles, many people are dying prematurely of age-related diseases. Heart attack remains the number-one killer. Kidney failure is a major problem in those fortunate enough to make it past 85 years of age.151 The diseases of aging can be related to an impaired glucose state that we hypothesize may be defined as fasting glucose levels chronically greater than 85 mg/dL.
Sugar levels higher than what cells require to sustain energy metabolism inflict greater damage than lower sugar levels. If moderate to high "normal" fasting glucose levels increase cardiovascular mortality by 40% (as was shown in one large human study), then high normal glucose (and the corresponding excess insulin secretion it provokes) could be one of the leading preventable risk factors for heart attack and stroke.
Because blood sugar levels over 126 mg/dL substantially increase the risk of disease, it might be logical to assume that levels somewhere below 126 also represent an unacceptable danger.
Our new hypothesis indicates that fasting blood glucose of greater than 85 mg/dL is a signal of a metabolic disturbance that may lead to the development of degenerative disease. Most aging people have glucose levels above 85, and this age group also suffers from a plethora of disease states.
1. Kikuchi S, Shinpo K, Takeuchi M, et al. Glycation? sweet tempter for neuronal death. Brain Res Brain Res Rev. 2003 Mar;41(2-3):306-23.
2. Hudson BI, Bucciarelli LG, Wendt T, et al. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem ?Biophys. 2003 Nov 1;419(1):80-8.
3. Haffner SM. Insulin resistance, inflammation, and the prediabetic state, Am J Cardiol. 2003 Aug 18;92(4A):18J-26J.
4. Manduteanu I, Voinea M, Antohe F, et al. Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur J Pharmacol. 2003 Sep 23;477(3):269-276.
5. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003 Oct;26(10):2754-7.
6. Jakus V. The role of nonenzymatic glycation and glyco-oxidation in the development of diabetic vascular complications. Cesk Fysiol. 2003 May;52(2):51-65.
7. Tauer A, Zhang X, Schaub TP, et al. Formation of advanced glycation end products during CAPD. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S57-60.
8. El-Assaad W, Buteau J, Peyot ML, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology. 2003 Sep;144(9):4154-63.
9. Lin RY, Reis ED, Dore AT, et al. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis. 2002 Aug;163(2):303-11.
10. Chia-Lin Li, Shih-Tzer Tsai, Pesus Chou. Comparison of metabolic risk profiles between subjects with fasting and 2-hour plasma glucose impairment. The Kinmen Study. Journal of Clinical Epidemiology 55 (1) (2002) pp. 19-24.
11. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002;51(6):597-604.
12. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care. 2002 Sep;5(5):561-8.
13. Gregg EW, Engelgau M, Narayan, V. Complications of diabetes in elderly people. BMJ October 26, 2002, Volume 325, Number 7370, pp. 916-917.
14. Maedler K, Spinas GA, Lehmann R, et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001 Aug; 50(8): 1683-90.
15. Ha H, Lee HB. Oxidative stress in diabetic nephropathy: basic and clinical information. Curr Diab Rep. 2001 Dec;1(3):282-7.
16. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev. 2001 Nov-Dec;17(6):436-43.
17. Kimura C, Oike M, Koyama T, Ito Y. Impairment of endothelial nitric oxide production by acute glucose overload. Am J Physiol Endocrinol Metab. 2001 Jan;280(1):E171-8.
18. Agardh E, Hultberg B, Agardh C. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Curr Eye Res. 2000 Jul;21(1):543-9.
19. Siskova A, Wilhelm J. Role of nonenzymatic glycation and oxidative stress on the development of complicated diabetic cataracts. Cesk Fysiol. 2000 Feb;49(1):16-21.
20. Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol. 2000;37(2):87-92.
21. Teixeira AS, Andrade SP. Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Life Sci. 1999;64(8):655-62.
22. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1998 Feb;21(2):326-7.
23. Levi B, Werman MJ. Long-term fructose consumption accelerates glycation and several age-related variables in male rats. J Nutr. 1998 Sep;128(9):1442-9.
24. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract. 1998 Aug;41(2):131-7.
25. Ren J, Gintant GA, Miller RE, Davidoff AJ. High extracellular glucose impairs cardiac E-C coupling in a glycosylation-dependent manner. Am J Physiol. 1997 Dec;273(6 Pt 2):H2876-83.
26. Larkins RG, Dunlop ME, Johnson EI. The pathogenesis of diabetic retinopathy. Aust N Z J Ophthalmol. 1996 May;24(2):97-104.
27. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996 Oct;28(5):419-26.
28. Howard EW, Benton R, Ahern-Moore J, Tomasek JJ. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp Cell Res. 1996 Oct 10;228(1):132-7.
29. Sugiyama S, Miyata T, Horie K, et al. Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant. 1996;11 Suppl 5:91-4.
30. Emekli, N. Nonenzymatic glycosylation of tissue and blood proteins. J. Marmara Univ. Dent. Fac. 1996 Sep; 2(2-3): 530-4.
31. Yarat A, Uguz Z, Ustunel A, Emekli N. Lens glutathione, lens protein glycation and electrophoretic patterns of lens proteins in STZ induced diabetic rats. Glycoconj J. 1995 Oct;12(5):622-6.
32. Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann N Y Acad Sci. 1995 Jan 17;748:562-70.
33. Ziyadeh FN. Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease. Miner Electrolyte Metab. 1995;21(4-5):292-302.
34.?Kaneto H, Fujii J, Suzuki K, et al. DNA cleavage induced by glycation of Cu,Zn-superoxide dismutase. Biochem J. 1994 Nov 15;304 (Pt 1):219-25.
35. Makino H, Shikata K, Kushiro M, et al. Roles of advanced glycation end-products in the progression of diabetic Nephropathy. Nephrol Dial Transplant. 1996;11 Suppl 5:76-80.
36. Winocour PD. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost. 1992 Nov 10;68(5):577-82.
37. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycation and the pathogenesis of diabetic complications. Ann. Intern. Med. 1984; 101: 527-37.
38. Walford RL, Harris SB, Gunion MW. The calorically restricted low-fat nutrient-dense diet in Biosphere 2 significantly lowers blood glucose, total leukocyte count, cholesterol, and blood pressure in humans. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11533-7.
39. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003 Jan 24; 299(5606): 572-4.
40. Lane MA, Ingram DK, Roth GS. Calorie restriction in nonhuman primates: effects on diabetes and cardiovascular risk. Toxicol. Sci. 1999 Dec; 52(2 Suppl.): 41-8.
41. Kemnitz JW, Roecker EB, Weindruch R, Elson DF, Baum ST, Bergman RN. Dietary restriction increases insulin sensitivity and lowers blood glucose in rhesus monkeys. Am. J.Physiol. 1994 Apr; 266(4, Pt. 1): E540-7.
42. Kent, S. BioMarker pharmaceuticals develops anti-aging therapy. Life Extension magazine 2003 Jun; 9(6): 56?7. Ft. Lauderdale, FL: Life Extension Foundation (http://www.lef.org/magazine/mag2003/2003_ preprint_bio_01.html?GO.X=9\&GO.Y=7).
43. Suh Y, Lee KA, Kim WH, Han BG, Vijg J, Park SC. Aging alters the apoptotic response to genotoxic stress. Nat. Med. 2002 Jan; 8(1):3-4.
44. Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br. J. Cancer 2002 May 20; 86(10): 1615-21.
45. Kritchevsky D. Caloric restriction and cancer. J. Nutr. Sci. Vitaminol. 2001 Feb; 47(1): 13-9.
46. Moreschi C. The connection between nutrition and tumor promotion. Z. Immunitaetsforsch. 1909; 2: 651.
47. Spindler SR. Reversing aging rapidly with short-term calorie restriction. Life Extension magazine 2001a; 7(12): 40?1. Ft. Lauderdale, FL: Life Extension Foundation (www.lef.org/magazine/mag2001/dec2001_ cover_spindler_04.html).
48. Yoshida K, Inoue T, Hirabayashi Y, Nojima K, Sado T. Calorie restriction and spontaneous hepatic tumors in C3H/He mice. J. Nutr. Health Aging 1999; 3(2): 121-6.
49. Wickner S, Mauriz M, Gottesmann S. Posttranslational quality control: folding, refolding, and degrading proteins. Science 1999 Dec 3; 286(5446): 1888-93.
50. Kritchevsky D. The effect of over- and under- nutrition on cancer. Eur. J. Cancer Prev. 1995 Dec; 4(6): 445-51.
51. Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 1999;22:45-49.
52. HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, ThirteenthEdition, McGraw-Hill, 1994.p. 2001 "In one study in normal persons (arterialized venous samples), insulin secretion ceased at a 4.6 nmol/L glucose (83mg/dl)..."
53. IBID., p.2004 "Plasma insulin concentration generally reaches background levels for the assay when plasma glucose falls below 4.6 nmol/L (83mg./dl). . ."
54. IBID. Table 328-4 Mean plasma glucose and insulin during fasting. [Zero values obtained after overnight fast. Results are mean values for 20 normal men and 60 normal women]
55. Heller RF. Hyperinsulinemic obesity and carbohydrate addiction: the missing link is the carbohydrate frequency factor. Med Hypotheses 1994 May;42(5):307-12.
56. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes. 2003 Sep;52(9):2191-7.
57. Bahceci M, Tuzcu A, Bahceci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest. 2003 Jul;26(7):655-9.
58. Fujiwara S, Emoto M, Komatsu M, et al. Arterial wall thickness is associated with insulin resistance in type 2 diabetic patients. J Atheroscler Thromb. 2003;10(4):246-52.
59. Taniguchi A, Fukushima M, Seino Y, et al. Platelet count is independently associated with insulin resistance in non-obese Japanese type 2 diabetic patients. Metabolism. 2003 Oct;52(10):1246-9.
60. Welin L, Bresater LE, Eriksson H, Hansson PO, Welin C, Rosengren A. Insulin resistance and other risk factors for coronary heart disease in elderly men. The Study of Men Born in 1913 and 1923. J Cardiovasc Risk. 2003 Aug;10(4):283-8.
61. Hitsumoto T, Iizuka T, Takahashi M, et al. Relationship between insulin resistance and oxidative stress in vivo. J Cardiol. 2003 Sep;42(3):119-27.
62. Festa A, Hanley AJ, Tracy RP, D'Agostino R Jr, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resist ance rather than decreased insulin secretion. Circulation. 2003 Oct 14;108(15):1822-30. Epub 2003 Sep 29.
63. Wiernsperger NF, Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab. 2003 Sep;29(4 Pt 2):6S77-87.
64. Brand-Miller JC. Glycemic load and chronic disease. Nutr Rev. 2003 May;61(5 Pt 2):S49-55.
65. Wolever TM, Mehling C. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr. 2003 Mar;77(3):612-21.
66. Li J, Kaneko T, Qin LQ, Wang J, Wang Y, Sato A. Long-term effects of high dietary fiber intake on glucose tolerance and lipid metabolism in GK rats: comparison among barley, rice, and cornstarch. Metabolism. 2003 Sep;52(9):1206-10.
67. Li J, Kaneko T, Wang Y, Qin LQ, Sato A. Effects of dietary fiber on the glucose tolerance in spontaneously diabetic rats?omparison among barley, rice, and corn starch. Nippon Eiseigaku Zasshi. 2003 May;58(2):281-6.
68. Liu S, Willett WC. Dietary glycemic load and atherothrombotic risk. Curr Atheroscler Rep. 2002;4(6):454-61.
69. Willett W, Manson J, Liu S. Glycemic index, glycemic load, and risk of type 2 diabetes. Am J Clin Nutr. 2002 Jul;76(1):274S-80S. 70. Preuss HG, Jarrell ST, Scheckenbach R, Lieberman S, Anderson RA. Comparative effects of chromium, vanadium and gymnema sylvestre on sugar-induced blood pressure elevations in SHR. J Am Coll Nutr. 1998 Apr;17(2):116-23.
71. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997 Nov;46(11):1786-91. 72. Baker B. Chromium supplements tied to glucose control. Family Practice News, 7/15/1996, pg 5.
73. Mirsky N. Glucose tolerance factor reduces blood glucose and free fatty acids levels in diabetic rats. J Inorg Biochem. 1993 Feb 1;49(2):123-8.
74. J.A. Vinson, K-H. Hsiao. Comparative Effect Of Various Forms Of Chromium On Serum Glucose: An Assay For Biologically Active Chromium. Nutritional Reports International, 32, (1), 1985.
75. Evans GW, Meyer L. Chromium picolinate increases longevity, Age (Chester) 15(4):p 135 1992. Twenty-second Annual Meeting of the American Aging Association and the Seventh Annual Meeting of the American College of Clinical Gerontology - San Francisco, California, USA ?October 16-20, 1992; 19921016.
76. Rosolova H, Mayer O Jr, Reaven G. Effect of variations in plasma magnesium concentrations on resistance to insulin-mediated glucose disposal in non-diabetic subjects. J. Clin. Endocrinol. Metab. 1997; 82: 3783-5.
77. Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med 1996 Jun 10;156(11):1143-8.
78. Paolisso G, Sgambato S, Gambardella A, et al. Daily magnesium supplements improve glucose handling in elderly subjects. Am. J. Clin.Nutr. 1992 Jun; 55(6): 1161-7.
79. Paolisso G, Scheen A, D'Onofrio F, Lefebvre P. Magnesium and glucose homeostasis. Diabetologia 1990;33:511-4.
80. Paolisso G, Passariello N, Pizza G, et al. Dietary magnesium supplements improve B-cell response to glucose and arginine in elderly non-insulin dependent diabetic subjects. Acta Endocrinol. Copenh. 1989 Jul; 121(1): 16-20.
81. Borenshtein D, Ofri R, Werman M, et al. Cataract development in diabetic sand rats treated with alpha-lipoic acid and its gamma-linolenic acid conjugate. Diabetes Metab Res Rev. 2001 Jan-Feb;17(1):44-50.
82. Midaoui AE, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens. 2003 Mar;16(3):173-9.
83. Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 Mar;26(3):770-6.
84. Dicter N, Madar Z, Tirosh O. Alpha-lipoic acid inhibits glycogen synthesis in rat soleus muscle via its oxidative activity and the uncoupling of mitochondria. J Nutr. 2002 Oct;132(10):3001-6.
85. Yilmaz O, Ozkan Y, Yildirim M, Ozturk AI, Ersan Y. Effects of alpha lipoic acid, ascorbic acid-6-palmitate, and fish oil on the glutathione, malonaldehyde, and fatty acids levels in erythrocytes of streptozotocin induced diabetic male rats. J Cell Biochem. 2002;86(3):530-9.
86. Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid, Endocr Pract. 2002 Jan-Feb;8(1):29-35.
87. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001 Oct;17(10):888-95.
88. Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther. 2000 Autumn;2(3):401-13.
89. Melhem MF, Craven PA, Derubertis FR. Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus. J Am Soc Nephrol. 2001 Jan; 12(1): 124-33.
90. Jain SK, Lim G. Lipoic acid decreases lipid peroxidation and protein glycosylation and increases (Na+ + K+)- and Ca++-ATPase activities in high glucose-treated red blood cells (RBC). Free Radical Biol. Med. 1998; 25: S94 (Abstr. 268); see also Free Radical Biol. Med. 2000; 29(11): 1122-8.
91. Khamaisi M, Rudich A, Potashnik R, Tritschler HJ, Gutman A, Bashan N. Lipoic acid acutely induces hypoglycemia in fasting nondiabetics and diabetic rats. Metabolism 1999 Apr; 48(4): 504-10.
92. Jacob S, Henriksen EJ, Ruus P, et al. The radical scavenger a-lipoic acid enhances insulin sensitivity in patients with NIDDM; a placebo controlled trial. Presented at Oxidants and Antioxidants in Biology, Santa Barbara, California, February 27-March 1, 1997.
93. Jacob S, Streeper RS, Fogt DL, et al. The antioxidant a-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes 1996 Aug; 45:1024-9.
94. Jacob S, Henriksen EJ, Schiemann AL, et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittelforschung 1995 Aug; 45(8): 872-4.
95. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther. 2003 May;25(5):1429-39.
96. Mingrone G, Greco AV, Capristo E, et al. L-carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr. 1999; 18(1): 77-82.
97. Pessotto P, Liberati R, Petrella O, Romanelli L, Calvani M, Peluso G. In experimental diabetes the decrease in the eye of lens carnitine levels is an early important and selective event. Exp. Eye Res. Feb 1997; 64: 195-201.
98. Yoshikawa H, Tajiri Y, Sako Y, Hashimoto T, Umeda F, Nawata H. Effects of biotin on glucotoxicity or lipotoxicity in rat pancreatic islets. Metabolism. 2002 Feb;51(2):163-8.
99. Furukawa Y. Enhancement of glucose-induced insulin secretion and modification of glucose metabolism by biotin. Nippon Rinsho. 1999 Oct;57(10):2261-9.
100. Romero-Navarro G, Cabrera-Valladares G, German MS, et al. Biotin regulation of pancreatic glucokinase and insulin in primary cultured rat islets and in biotin-deficient rats. Endocrinology. 1999 Oct;140(10):4595-600.
101. McCarty MF. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Med Hypotheses. 1999 May;52(5):401-6.
102. Tsunoda K, Osada K, Komai M, et al. Effects of dietary biotin on enhanced sucrose intake and enhanced gustatory nerve responses to sucrose seen in diabetic OLETF rat. J Nutr Sci Vitaminol (Tokyo). 1998 Apr;44(2):207-16.
103. Zhang H, Osada K, Maebashi M, Ito M, Komai M, Furukawa Y. A high biotin diet improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus. J Nutr Sci Vitaminol (Tokyo). 1996 Dec;42(6):517-26.
104. Borboni P, Magnaterra R, Rabini RA, et al. Effect of biotin on glucokinase activity, mRNA expression and insulin release in cultured beta-cells. Acta Diabetol. 1996 Jul;33(2):154-8.
105. Koutsikos D, Fourtounas C, Kapetanaki A, et al. Oral glucose tolerance test after high-dose i.v. biotin administration in normoglucemic hemodialysis patients. Ren Fail. 1996 Jan;18(1):131-7.
106. Koutsikos D, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. Biomed. Pharmacother. 1990; 44: 511-4.
107. Reddi A, DeAngelis B, Frank O, Lasker N, Baker H. Biotin supplementation improves glucose and insulin tolerances in genetically diabetic KK mice. Life Sci. 1988;42(13):1323-30.
108. Zhang H, Osada K, Sone H, Furukawa Y. Biotin administration improves the impaired glucose tolerance to streptozotocin-induced diabetic Wistar rats. J Nutr Sci Vitaminol. 1997; 43: 271-80.
109. Jones P, Yate P. Contraindications to the use of metformin, BMJ 2003;326:4-5 (4?anuary).
110. Wulffele MG, Kooy A, Lehert P, et al. Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes. Diabetes Care 25:2133-2140, 2002.
111. Diabetes Prevention Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng. J Med, 2002, bol 346, pp. 393-403.
112. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2?iabetes. Pediatrics (online) 2001;107:e55.
113. Klow NE, Draganov B, Os I. Metformin and contrast media-inc
Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.
While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.